» Articles » PMID: 32007101

Mechanical Factors Tune the Sensitivity of Mdx Muscle to Eccentric Strength Loss and Its Protection by Antioxidant and Calcium Modulators

Overview
Journal Skelet Muscle
Specialty Physiology
Date 2020 Feb 3
PMID 32007101
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dystrophin deficiency sensitizes skeletal muscle of mice to eccentric contraction (ECC)-induced strength loss. ECC protocols distinguish dystrophin-deficient from healthy, wild type muscle, and test the efficacy of therapeutics for Duchenne muscular dystrophy (DMD). However, given the large lab-to-lab variability in ECC-induced strength loss of dystrophin-deficient mouse skeletal muscle (10-95%), mechanical factors of the contraction likely impact the degree of loss. Therefore, the purpose of this study was to evaluate the extent to which mechanical variables impact sensitivity of dystrophin-deficient mouse skeletal muscle to ECC.

Methods: We completed ex vivo and in vivo muscle preparations of the dystrophin-deficient mdx mouse and designed ECC protocols within physiological ranges of contractile parameters (length change, velocity, contraction duration, and stimulation frequencies). To determine whether these contractile parameters affected known factors associated with ECC-induced strength loss, we measured sarcolemmal damage after ECC as well as strength loss in the presence of the antioxidant N-acetylcysteine (NAC) and small molecule calcium modulators that increase SERCA activity (DS-11966966 and CDN1163) or lower calcium leak from the ryanodine receptor (Chloroxine and Myricetin).

Results: The magnitude of length change, work, and stimulation duration ex vivo and in vivo of an ECC were the most important determinants of strength loss in mdx muscle. Passive lengthening and submaximal stimulations did not induce strength loss. We further showed that sarcolemmal permeability was associated with muscle length change, but it only accounted for a minimal fraction (21%) of the total strength loss (70%). The magnitude of length change also significantly influenced the degree to which NAC and small molecule calcium modulators protected against ECC-induced strength loss.

Conclusions: These results indicate that ECC-induced strength loss of mdx skeletal muscle is dependent on the mechanical properties of the contraction and that mdx muscle is insensitive to ECC at submaximal stimulation frequencies. Rigorous design of ECC protocols is critical for effective use of strength loss as a readout in evaluating potential therapeutics for muscular dystrophy.

Citing Articles

Dysregulated ATX-LPA and YAP/TAZ signaling in dystrophic Sgcd mice with early fibrosis and inflammation.

Gutierrez-Rojas C, Cordova-Casanova A, Faundez-Contreras J, Cruz-Soca M, Gallardo F, Bock-Pereda A Skelet Muscle. 2025; 15(1):6.

PMID: 40050938 PMC: 11884125. DOI: 10.1186/s13395-025-00375-5.


Impaired hydrogen sulfide biosynthesis underlies eccentric contraction-induced force loss in dystrophin-deficient skeletal muscle.

Southern W, Johnson E, Fasbender E, Fallon K, Cavazos C, Lowe D J Clin Invest. 2025; 135(5).

PMID: 39808494 PMC: 11870723. DOI: 10.1172/JCI176942.


Exploring lipin1 as a promising therapeutic target for the treatment of Duchenne muscular dystrophy.

Jama A, Alshudukhi A, Burke S, Dong L, Kamau J, Morris B J Transl Med. 2024; 22(1):664.

PMID: 39014470 PMC: 11253568. DOI: 10.1186/s12967-024-05494-z.


Time-of-day effects on ex vivo muscle contractility following short-term satellite cell ablation.

Kahn R, Lieber R, Meza G, Dinnunhan F, Lacham-Kaplan O, Dayanidhi S Am J Physiol Cell Physiol. 2024; 327(1):C213-C219.

PMID: 38586876 PMC: 11371314. DOI: 10.1152/ajpcell.00157.2024.


Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy.

Russell A, DuVall M, Barthel B, Qian Y, Peter A, Newell-Stamper B J Clin Invest. 2023; 133(10).

PMID: 36995778 PMC: 10178848. DOI: 10.1172/JCI153837.


References
1.
Straub V, Rafael J, Chamberlain J, Campbell K . Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 1997; 139(2):375-85. PMC: 2139791. DOI: 10.1083/jcb.139.2.375. View

2.
Barton E, Morris L, Musaro A, Rosenthal N, Sweeney H . Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002; 157(1):137-48. PMC: 2173262. DOI: 10.1083/jcb.200108071. View

3.
Bellinger A, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L . Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med. 2009; 15(3):325-30. PMC: 2910579. DOI: 10.1038/nm.1916. View

4.
Gehrig S, Ryall J, Schertzer J, Lynch G . Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp Physiol. 2008; 93(11):1190-8. DOI: 10.1113/expphysiol.2008.042838. View

5.
Loehr J, Stinnett G, Hernandez-Rivera M, Roten W, Wilson L, Pautler R . Eliminating Nox2 reactive oxygen species production protects dystrophic skeletal muscle from pathological calcium influx assessed in vivo by manganese-enhanced magnetic resonance imaging. J Physiol. 2016; 594(21):6395-6405. PMC: 5088246. DOI: 10.1113/JP272907. View